Madrigal Pharmaceuticals (MDGL) Change in Account Payables (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Change in Account Payables for 17 consecutive years, with -$21.1 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Change in Account Payables fell 417.91% year-over-year to -$21.1 million; the TTM figure through Jun 2026 stood at -$6.6 million (down 122.94% YoY), while the FY2025 annual figure was $5.3 million, down 66.07% from the prior year.
• Change in Account Payables declined to -$21.1 million in Q2 2026 per MDGL's latest filing, from $3.6 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $37.0 million in Q3 2024 and bottomed at -$21.1 million in Q2 2026.
• Historically, Change in Account Payables has averaged $552555.6 across 5 years, with a median of $204000.0 in 2022.
• Annual changes were most pronounced in 2023 — Change in Account Payables sank 935.93% — and 2024, when it soared 3827.02%.
• Madrigal Pharmaceuticals' Change in Account Payables stood at $5.3 million in 2022, then soared by 118.24% to $11.5 million in 2023, then plunged by 120.58% to -$2.4 million in 2024, then surged by 308.79% to $4.9 million in 2025, then slumped by 527.68% to -$21.1 million in 2026.
• Business Quant data shows MDGL's Change in Account Payables at -$21.1 million in Q2 2026, $3.6 million in Q1 2026, and $4.9 million in Q4 2025.